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ABSTRACT
In the present study, the contractility of isolated
cardiac muscle obtained from normotensive and treated or
untreated hypertensive rat hearts were investigated.

The

effects of inotropic agents were also explored •
. Some SHRs were subjected to chronic antihypertensive
treatment.

After their blood pressure had been lowered,

positive and negative inotropic agents were used to study
the papillary muscles.

The effects of acidosis, increased

extracellular calcium, hypoxia, and reoxygenation on the
isolated papillary muscles obtained from their hearts were
studied.

The same was done for isolated cardiac muscles

that were removed from WKYs and SHRs.

Isoproterenol in the

absence or presence of propranolol was also used to investigate the contractility of SHRs and WKYs.
Clonidine, alpha-methyldopa, and verapamil all
reduced the blood pressures of SHRs which were on chronic
antihypertensive therapy.

When propranolol was added to

the muscle bath, the developed tension of the SHRs was
significantly higher than that of the WKYs by 13.1%
(p<O.OS) after 5 minutes of the addition showing that
SHRs and WKYs behaved differently during this intervention.
During the isoproterenol intervention in the absence of
propranolol, the maximal rate of tension development after
iii
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10 minutes of addition of isoproterenol of the SHRs was
significantly lower than their control measurement, while
that of the WKYs was equal to their control.

Also the time

to maximal relaxation of the WKYs was significantly lower
than the control.

There was no change observed for the

SHRs in their time to maximal relaxation before and after
the isoproterenol was added to the bath.

The developed

tension and maximal rate of tension development of the WKYs
improved significantly when isoproterenol was added to the
bath following propranolol intervention.

Overall the

isoproterenol did not have any significant inotropic effect
on SHRs and WKYs.

During acidosis, the WKYs and pretreated

rats responded equally but significantly lower than the SHRs.
The developed tension, maximal rate of t ension development,
and maximal rate of tension decline of WKYs were significantly higher than those of the SHRs after 5 minutes of
hypoxia showing the the SHRs responded to these interventions
differently from the WKYs.
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Chapter 1
INTRODUCTION
Hypertension, which affects a large portion of the
world's population, continues to be a major risk factor in
the premature development of serious cardiovascular disease.
Diseases of the heart and of the blood vesse ls remain the
leading cause of death in most western countries.
Although hypertension is an extremely complex
disease-state, long-term effective symptomatic control by
drugs has been proven possible (Abrams, 1980; Freis , 1976;
Gross, 1977; Saxena and Forsythe, 1976; Schmitt, 1977;
Van Zweiten, 1975).

The purpose of this study was to deduce

the effects of selected drugs on human essential hypertension by examining their effects on normotensive and hypertensive laboratory rats.
Development of Spontaneously
Hypert·e nsi ve Rat
In an effort to develop a genetic animal model of
human essential hypertension, Okamoto and Aoki examined the
blood pressures of several hundred rats from the Wistar
colony of the animal center at Kyoto University in 1963.
The blood pressures in these rats averaged from 120 to 140 mm
Hg as measured by tail-plethysmograph techniques without

1
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anesthesia.

One of the male rats examined exhibited a blood

pressure reading of 145-175 mm Hg.

A female rat with a

blood pressure reading of 130-140 mm Hg was chosen for
mating with this male rat.

During the period 1959-1960, the

male rat· maintained a sustained elevated blood pressure
(higher than 150 mm Hg).

Mating between the pair was repeated

four times.
The offspring of these matings consisted of 16 males
and 20 females.

All were fed a normal laboratory diet.

Of

these, 12 males and 6 females were found, at the age of 20
weeks, to have sustained blood pressures above 150 mm Hg; 14
males and 11 females were found to have similar sustained
blood pressures at the age of 40 weeks.

The offspring that

exhibited hypertension for over 1 month were used for further
brother-sister matings.

Successive generations of hyper-

tensive animals were obtained by brother-sister matings of
animals with sustained high blood pressure.

Mean blood

pressures increased with each succeeding generation, reaching a plateau by about the sixth generation (F ).
6

This

process was continued until a colony of rats was produced
in which blood pressures were uniformly more than 180 rom Hg
by 20 weeks of age.
The typical lesions (altered peripheral resistance,
altered sensitivity to catecholamines, and altered handling
of calcium by vascular smooth muscle and probably by cardiac
muscle as well) often associated with human essential

3

hypertension were frequently observed in these rats,
suggesting that the rats might be good models for the study
of human disease.

The animals were called Spontaneously

Hypertensive Rats (SHRs)

(Okamoto, 1962; Okamoto, 1969;

Okamoto and Aoki, 1963).
Successive brother-sister matings were continued in
order to produce an inbred strain of SHR rats, which was
obtained in October 1969 (Okamoto et al., 1972).

This inbred

strain was in the thirty-sixth generation in 1974.

The

colony of rats maintained at Kyoto University numbers some
2,000 animals.

Animals derived from this co l ony have been

introduced into about 200 insti tut ions.
Experience in many laboratories indicates that, for
comparative purposes, only the parent--Wistar Kyoto normotensive (WKY)--can

s~rve

as an adequate control for

experimentation with SHRs .

It should be emphasized, h 6wever,

that the SHR strain has been subjected to selection , which
might have the effect of fixing genes that are still
segregating in the WKY rat strain.
i]

Symptomatically , the disease entity of this animal
model closely resembles human hypertension, eve n though the

J
i

etiology of the disease may be different from that of most
cases of human essential hypertension.

Laboratory use of

SHRs has been largely limited to studies relating to hypertensive disorders, although several other abnormalities do
exist in SHRs and others may become apparent in future
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studies.

The use of the SHR as a model for genetic hyper-

tension is widely accepted, as illustrated in a review by
Trippodo and Frohlich (1981).

Some controversy regarding

its use, however, still exists, as pointed out by McGiff
and Quilley (1981).
SHR offers a unique model for studying the natural
development of cardiac hypertrophy and its reversal by drug
therapy (Sen et al., 1974).

One such investigation led to

the suggesti on that factors other than arterial pressure are
involved in the development of cardiac hypertrophy in hypertension (Sen et al., 1974).

The same study uncovered the

different effects of antihypertensive drugs, including their
effecti veness in the reversal of cardiac hypertrophy (Sen
et al., 1974).

Sen, Tarazi and Bumpus (1977) reported

results that suggested that factors other than blood
pressure control play a significant role in the reversal of
cardiac hypertrophy by antihypertensive therapy.
Antihypertensive Drugs
An understanding of the sites and mechanisms of
action of traditional antihypertensive agents, as well as of
the pathophysiologic factors involved in the genesis of
hypertension, may l ead to the development of more efficacious and less toxic drugs.

This study was limited to a

review of three types of antihypertensive interventions :
(1) beta-adrenoceptor antagon is ts,

(2) alpha-adrenoceptor

agonists, and (3) Ca++_antagonist-vasodilators.

5

Beta-adrenoceptor Antagonist:
Propranolol
The introduction of beta-blocking agents for the
treatment of arrhythmias and angina (Dornhorst and Robinson,
1962) was followed by the identification of the antihypertensive properties of propranolol (Prichard and Gillam, 1964).
Although early investigators exhibited some reservations
regarding the significance of the antihypertensive effect
(Richardson, Freund, and Gear, 1968; Paterson and Dollery,
1966), a clear antihypertensive action was later confirmed
by others (Hannsson, Malmcrona and Olander, 1972; Zacharias
and Cowen, 1972).

Thus the effectiveness of beta-blockers

for a large portion of hypertensive patients has been
established.
The mechanism of the antihypertensive action of the
beta-adrenoceptor blocking agent propranolol is largely
unknown.

What is known is that beta-adrenergic antagonists

without intrinsic sympathomimetic activity, such as pro- ·
pranolol, decrease heart rate and cardiac output, prolong
and decrease the velocity of mechanical systole and slightly
decrease blood pressure in resting subjects (Helfant, Herman,
and Gorlin, 1971; Robin et al., 1976).

Peripheral resistance

is increased as a result of compensatory sympathetic reflexes,
and blood flow to all tissues e x cept the brain is reduced
(Nies, Evans, and Shand, 1973).

Beta-adrenergic blocking

agents have minimal direct effects on the peripheral vasculature, although propranolol causes a brief vasodilation

6
unrelated to beta-receptor blockade when injected intraarterially (Shanks, ·1967).

The major effects of propranolol

on the heart are absent in animals whose norepinephrine
stores have been depleted (Shanks, 1966).
Experience with the different beta-adrenoceptor
antagonists provides strong evidence to indicate that their
reduction in arterial blood pressure is primarily the result
of a beta-adrenergic blockade.

Beta blockade in the juxta-

glomerular apparatus of the kidney and in the heart, brain,
postganglionic sympathetic nerve terminal, and vascular
smooth muscle has been postulated as the primary mechanism
at the target sites contributing to the antihypertensive
effects of the beta blockers (Fitzgerald, 1975; Meier et al.,
1980; Saxena and Forsyth, 1976; Scriabine, 1979).
The mechanism by which propranolol reduces nonadrenaline release has been postulated by

Adler-Graschvisky

and Langer (1975) to be presynaptic beta-receptor blocks.
Kalsner (1980), however, challenged this hypothesis.
The spontaneously hypertensive rat is a commonlyused model for studying pathogenic mechanisms and therapy
of essential hypertension.

A number of conflicting reports

describe differing effects of propranolol in SHRs.

Some

authors reported that propranolol had no significant effect
on blood pressure in spontaneously hypertensive rats, or
even caused a slight rise (Forman and Mulrow, 1974; Levy,
1976; Numao and Iriuchijima, 1974).

Others found a
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hypotensive action (Garvey and Ram, 1975; Sweet et al., 1976;
Vavra, Tom, and Greslin, 1973).

Smits, van Essen, and

Struyker-Boudier (1980) showed that a lowering of blood
pressure similar to that in hypertensive patients could be
obtained if propranolol were delivered chronically, using
osmotic minipumps, to the conscious unrestrained spontaneously hypertensive rat.
Alpha-adrenoceptor Agon ist:
Clonidine
The antihypertensive effect of clonidine was first
discovered serendipitously in 1962 when Dr. M. Wolf administered to himself and his secretary a few drops of a 0.3%
solution (1-2 mgj of c l onidine .

He immediately noted its

sedative, bradycardiac and hypotensive e ffects as well as its
decongestant properties (Graubner and Wolf, 1966; Kobinger,
1978; Wolf and Morr, 1977).
Clonidine was originally developed as a nasal
decongestant, based on its chemical similarity with other
imidazolines, which demonstrated vasoconstricting effects.
It was by chance that Dr. Wolf discovered the pronounced
blood pressure lowering and sedative properties of the drug.
Since that discovery, clonidine has been widely u sed as an
antihypertensive (Kobinger, 1978; Schmitt, 1977; Van Zwieten,
1975).

It has also been used successfully in mitigating

severe withdrawal symptoms of opiate addicts (Gold, Redmond,
and Kleber, 1978).
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Clonidine is an alpha adrenergic receptor agonist
that selectively stimulates postsynaptic

alpha~adrenergic

receptors in the depressor site of the vasomotor center of
the medulla oblangata (Griep, 1978; Haeusler, 1974; Haeusler,
Finch, and Thoenen, 1972; Henning, 1975; Kosman, 1975;
Pettinger, 1975; Schmitt, 1969) in the region of the nucleus
of the solitary tract (NTS) or locus coerculeus (Cedarbaum
and Aghajanian, 1977; Gold, Redmond, and Kleber, 1978;
Henning, 1975; Kobinger, 1978; Svensson, Bunny, and Aghajanian, 1975).

Activation of these central alpha-adrenergic

receptors diminishes the efferent sympathetic neuronal
vasoconstrictor tone to the heart, kidneys and peripheral
vasculature, causing vasodilation and lowering blood
pressure (Griep, 1978; Haeusler, 1974; Haeusler, Finch, and
Thoenen, 1972; Hoobler and Kashina, 1977; Kosman, 1975;
Pettinger, 1975; Schmitt, 1969).
Although clonidine stimulates the postsynaptic
alpha-adrenergic receptors, it actually has both preganglionic and postganglionic alpha-adrenergic agonist-properties
with variable potency in different organs (Kobinger, 1978).
Clonidine may also influence blood pressure through alphaadrenergic receptors in suprabulbar structures such as the
hypothalamus (Kobinger, 1978).
The reduced sympathetic activity associated with
clonidine is correlated with a decrease in plasma and
urinary catecholamines, especially norepinephrine (Hokfelt,
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Hedeland,and Dymling, 1970; Whitsett, Chrysant,and Dillard,
1978).
Furthermore, it has been shown that small initial
doses of clonidine lowers blood pressure.

As the dose is

increased, the blood pressure becomes refractory to the
action of the drug (Conolly et al., 1972).

Clonidine

(0.1mgkg- 1 , orally) has been found to result in a marked
fall in blood pressure in Spontaneously Hypertensive Rats
(Dadkar, Aroskar, and Dohadwalla, 1979).
Onesti, Schwartz, and Kim (1969 and 1971) found that
acute oral administration of clonidine consistently reduced
blood pressure and cardiac output in patients in a supine
position.

The reduction in cardiac output was attributed to

a decrease in both heart rate and stroke volume, and no
consistent changes in total peripheral
in patients in a supine position.

resista~ce

were found

However, oral administra-

tion to patients in an upright position caused a significant
reduction in total peripheral resistance.

Brod, Horbach,

and Just (1972); McRaven, Kroetz, and Kioschos (1971);
Muir, Burton, and Lawrie (1969) and Vorburger, Butikofer,
and Reubi (1968) reported similar hemodynamic effects after
acute administration of clonidine.
Alpha-adrenoceptor Agonist:
Alpha-methyldopa
Alpha-methyldopa was shown to be an effective
inhibitor of L-aromatic amino acid (dopa) decarboxylase by
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Sourkes (1954) but it did not attract major attention until
its hypotensive properties were noted during studies of
aromatic acid metabolism in man (Oates et al., 1960).

It

has since come to be one of the major agents used in the
treatment of essential hypertension.
The mechanism of action of the drug in lowering blood
pressure has been the subject of much investigation and some
controversy (Henning, 1969: Muscholl, 1966; Stone and Porter,
1966).

The discovery of the presence of alpha-methyldopamine

and alpha-methylnoradrenaline, metabolic products of alphamethyldopa, in the brains and hearts of mice treated with
alpha-methyldopa (Carlsson and Lindqvist, 1962) was followed
by the report that alpha-methyldopa and its metabolic
products restored responses to sympathetic nerve stimulation
in animals depleted of neuronal noradrenaline by reserpine
(Day and Rand, 1963, 1964).

The later workers suggested

that in patients receiving alpha-methyldopa, alphamethylnoradrenaline formed by decarboxylation and betahydroxylation might assume the transmitter function of
noradrenaline.

Since alpha-methylnoradrenaline was shown

to possess weaker sympathominetic properties than noradrenaline (Day and Rand, 1964) the "false transmitter" would lead
to a partial sympathetic nerve blockade which might account
for the symptoms of partial sympathetic impairment reported
clinically (Bayliss and Harvey-Smith, 1962; Dollery and
Harington, 1962).
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The false transmitter hypothesis was supported by
the demonstration of alpha-methylnoradrenaline release
from sympathetic nerve after alpha-methyldopa pretreatment
(Muscholl and Maitre, 1963) and by a report that inhibition
of dopa decarboxylase abolished the antihypertensive effect
of alpha-methyldopa (Davis et al., 1963).

The antihyper-

tensive action of alpha-methyldopa has been variously
attributed to the false transmitter hypothesis and the
alpha-agonist property (Dollery and Bulpitt, 1975; Henning,
1975; Kobinger, 1978).
Alpha-methyldopa causes progressive reductions in
blood pressure and heart rate.

The decrease in blood

pressure has been reported to be due to decreases in cardicac
output, peripheral resistance, or both (Lund-Johansen, 1972).
Alpha-methyldopa has been shown to decrease blood
pressure in rats (Day, Roach, and Whiting, 1973; Filczewski
and Boqucka, 1979).
Ca++_Antagonist-Vasodilators:
Verapamil
One of the most exciting and interesting of the
vasodilator type of antihypertensives is the calcium
antagonist.

The prototypes of this class of vasodilators

are the chemically dissimilar compounds verapamil, diltiazem,
and nifedipine.

They appear to differ in certain aspects of

pharmacologic profile; e.g., verapamil has a greater effect
on myocardial AV conduction than nifedipine, whereas
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nifedipine appears to have a greater blood pressure lowering
action.
Verapamil, a synthetic papaverine derivative, was
first introduced as a smooth muscle relaxant with potent
peripheral as well as coronary vasodilator properties in
laboratory animals (Hass and Hartfelder, 1962; Melville and
Benfey, 1965; Melville, Shister, and Hug, 1964; Nayler et al.,
1968) and in humans (Luebs et al., 1966; Mignault, 1966).
Verapamil has been used for many years in the treatment of
angina and various cardiac arrhythmias and is particularly
useful in patients with airways disease.

Several studies

have shown verapamil to be as effective as beta blockers in
the treatment of these conditions (I.ivesley et al., 1973;
Sandler, Clayton, and Thornicroft, 1968).
Although the primary therapeutic use of verapamil
is as an antiarrhythmic and antianginal agent, some clinical
studies have raised the possibility that verapamil may also
be of value both in the management of acute hypertensive
crises and in the treatment of essential hypertension
(Lewis et al., 1979; Singh, Ellrodt, and Peter, 1978).
Other findings indicate that the antihypertensive action of
veraparnil is not sufficiently potent for the drug to be
effective in the treatment of arterial hypertension without
concurrent antihypertensive therapy (Pedersen, 1978).
Stoker, and Stokes (1979) have shown verapamil to be a
potent and effective hypotensive agent.

Oates,
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Veraparnil appears to exert its pharmacological
effects primarily through calcium antagonism at the cell
membrane of excitable tissues, impairing the entry of
calcium ions into the cell during depolarization.

This

decreases the strength of contraction of cardiac and vascular smooth muscle, the latter effect producing peripheral
vasodilation.

Theoretically, this combination of peripheral

vasodilation and reduction in cardiac contraction should
produce a decline in blood pressure.

Following intravenous

injection, varaparnil has been demonstrated to cause hypotension in both normal and hypertensive patients (Brittinger
et al., 1970).

A hypotensive effect has been noted in some

angina studies where larger doses of the drug were used
(Livesley et al ., 1973; Sandler, clayton, and Thornicroft,
1968).
Isolated Cardiac Muscle
Papillary muscles from either the right or left
ventricle are often used for studying the effects of drugs
or other interventions on cardiac muscle mechanics.
Isolated papillary muscle has been shown to be a representative model of the intact myocardium (Sonnenblick, 1962;
Sonnenblick, Braunwald, and Morrow, 1965).

Since Cattel

and Gold's work in 19 38 , isolated cardiac muscle has been
used in experiments.
by A.

v.

Muscle mechanics were described first

Hill, the recipient of the 1923 Nobel Prize for
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physiology and medicine for skeletal muscle.

He described

the "active state" (1938) and showed that it had intensity
and duration (Hill, 1949, 1953).

The intensity of the

active state refers to the instantaneous rate of force
development and is proportional to the maximal value of the
first derivative of tension (dT/dt) .

The duration of the

active state is the amount of time it takes for the muscle
to develop its maximal tension; therefore, it is related to
the time to peak tension (TPT) .

Application of the princi-

ples of skeletal muscle mechanics to the analysis of
cardiac muscle performance began in 1959 with studies of
Abbott and Mommaerts and later those of Sonnenblick (1964)
and Brady (1967).
The difference in skeletal muscle and cardiac muscle
is that cardiac muscle must be prestretched and this elicits
resting tension.

There is a length (Lmax) of which maximum

developed tension occurs; stretching beyond this length
overstretches the muscle and results in a decline in developed tension.

As resting length is increased, resting

tension also increases.

This increased force seen with

increased initial length characterizes the Frank-Starling
principle (Frank, 1895; Starling, 1918) derived initially
in the intact heart.
relaxation.

This phenomenon is known as stress

In the heart muscle a second general principle

is also observed which does not generally obtain in
skeletal muscle, namely changing "contractility."

In the
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isometric contraction, a change in contractility, induced
by an inotropic intervention, is characterized by a change
in the rate of tension development (dT/dt) from any initial
length.

The increase in dT/dt is usually, but not always,

accompanied by an increase in developed tension (Sonnenblick,
1962).
Inotropic Agents
Interventions that increase dT/dt are termed
positive inotropic agents, .while those that depress dT / dt
are known as negative inotropic agents.
Calcium
Calcium is a positive inotropic agent, and calcium
ions are intimately involved in the contraction of cardiac
muscle.

Calcium transport by the sarcoplasmic reticulum is

a major mechanism by which intramyocardial levels of calcium
and, thereby, tension development are modulated (Ebashi,
Endo, and Ohtsuki, 1971).

Participation of the sarcoplasmic

reticulum in such regulatory processes depends on its
ability to sequester calcium by an energy consuming process
and, as a consequence, promote relaxation of myofibrils
(Weber and Murray, 1973).

In addition, the sarcoplasmic

reticulum may serve as an intrace llular source of "activator " calcium, the release of which turns on the contractile

16

machinery following cardiac cell membrane depolarization.
Changes in the capacity of sarcoplasmic reticulum to
sequester calcium efficiently would, there fore, be expected
to have an important impact on the contractile performance
of the heart.
Limas and Cohn (1977), found that sarcoplasmic
reticula of spontaneously hypertensive rats exhibited
depressed calcium uptake and binding.

Aoki et al.

(1974a)

also found that sarcoplasmic reticula from hypertensive
rat hearts showed low calcium binding capacity, and they
concluded that this could induce contracture in hypertensive cardiac muscle.

Heller (1977), using the papillary

muscle, observed accentuated aftercontractions without
st~mulus

in SHRs, suggesting decreased resequestration of

calcium by the sarcoplasmic reticulum.

This s uggesti on

was supported by Hamre ll and Alpert (1976), who us ed an
isolated papillary muscle preparation and found that
muscles from hypertensive rat hearts took a longer time
for isometric relaxation than did muscles from normotensive rat hearts; this indicates a decreased rate of calcium
resequestration.
Acidosis
The negative inotropic effect of acidosis on
cardiac muscle has been frequently demonstrated both in
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vivo and in vitro since the first report by Klug in 1879
and the detailed study of Smith in 1956.

Since then,

intracellular acidosis has been regarded as of major
clinical importance as a cause of reduced cardiac function
both in ischemia and heart failure (Katz and Hecht, 1969;
Schwartz et al., 1973).
The mechanism of altered myocardial contractility
in acidosis has not been fully elucidated, but many sites
of action for H+ have been considered.

Katz and Hecht

(1969); Fuchs, Reddy, and Briggs (1970); and Nakamuru and
Schwartz (1970) postulated that, at low pH, excess hydrogen
ions (H+) compete with calcium ions (ca++) for binding sites
to the myocardial protein troponin and increase the binding
of calcium ions (ca++) to the sarcoplasmic reticulum.

This

competition decreases the number of binding sites on troponin available for ca++ at a lowered pH, thus decreasing the
amount of stored ca++ available for release upon excitation.
The dependence of the heart on extracellular ca++ for
contraction supports the theory that Ca

++

-H

+

interaction

accounts for the decline in ventricular performance (contractility) during acidosis.
Hypoxia and Reoxygenation
The effects of hypoxia on papillary muscle preparations have been studied in some detail.

Hypoxia induces a
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reduction in, or even loss of, the contractile state
(Bing, Brooks, and Messer, 1973; Buccino et al., 1967;
Greene and Weisfeldt, 1974; Kent et al., 1972; Lee et al.,
1961; Tyberg, Parmley, and Sonnenblick, 1969; Winbury, 1956).
Both the intensity and duration of the active state are
diminished, since both the rate of tension development and
time to peak tension decline (Buccino et al., 1967; Nakhjavan
et al., 1971; Tyberg et al., 1970).

Most papillary muscle

preparations are made hypoxic with a gas mixture of 95 %
nitrogen and 5 % carbon dioxide or with a mixture of 85 %
nitrogen and 15% carbon dioxide.

Under these conditions,

negative inotropic effects are seen with the first 5 minutes
of hypoxia (Lee et al., 1961; Nakhjavan et al., 1971;
Tyberg et al., 1970).
When muscles are reoxygenated after an hypoxic
period, a marked prolongation of time to peak tension and
relaxation is observed soon after reoxygenation is begun,
which then gradually shortens as force development incre ases
later in the reoxygenation period (Bing, Brooks, and Messer,
1968; Nakhjav an et al., 1971; Tyberg et al., 1970).

Taubert,

Bufalino, and Amico (1980) found that, at the end of the
first hour of hypoxia, the maximum rate of tension development was depressed by 50-60 % in all of the four subgroups
studied.

At the peak inotropic effect of increased Ca++,

however, differences in muscle performance were noted.

When

++
Ca
was raised from 1.0 to 2.5mM, dT/dt was increased by
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81% in the SHRs and by 47% in WKYs.

These increases were

significantly different from each other.

When Ca ++ was

elevated from 2.5 to 5.0mM, dT/dt was increased by 25% in
the SHRs but did not change in WKYs.

This showed that

hypertensive and n ormotensive cardiac muscle respond similarly to the negative effects of hypoxia, but differ in
their responses to the addition of extracellular calcium
during this period.
Hypoxia and reoxygenation can be associated with
calcium overload within the cardiac cell, which can lead to
decline of mechanical function.

Hypoxia at l ow pH, however,

can prevent much of this calcium overload.

The phenomenon

of calcium overload during hypoxia and reoxygenation has not
been examined in hypertensive cardiac muscle, but Lakatta ,
Nayler, and Poole-Wilson (1979) measured mechanical function
and calcium accumulation in isolated normotensive muscle.
They found that when hypoxia was induced at a low pH (6.8),
subsequent reoxygenation at normal pH was not associated
with calcium overload or the development of contracture.
The greatest calcium overload occurred in the reoxygenation
period after hypoxia at normal pH.
Isoproterenol
Isoproterenol is the most active of the sympathomimetic amines.

It acts almost exclusive ly on beta receptors

by virtue of N-alkyl substitution and has essentially no
action on alpha receptors.

Isoprote r e nol was f irst studied
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by Konzett in 1940 and has since been the subject of extensive animal and clinical research.
Isoproterenol has a positive inotropic effect in
mammalian myocardium.

It is generally believed that the

positive inotropic actions of isoproterenol result from an
increase in calcium influx via the slow inward current
coupled with an increase in the ability of intracellular
organelles, notably the sarcoplasmic reticula, to hand le
the increased calcium load.

Thus, not only is more calcium

admitted into the cell during each contraction cycle, but a
greater amount of calcium in releasable intracellular stores
is available for contraction (Schol z , 1980).

This effect of

isoprotereno l on calcium appears to be mediated by cyclic
adenosine 3'5' monophosphate (cyclic AMP)
1977; Robinson et al., 1965).

(Kelly and Corbin,

Most of the effects of cyclic

AMP in mammalian tissues are modulated by changes in the
activity of cyclic AMP--dependent pro t ein kinase.

Beta

receptor blockade, on the other hand, produces metabolic
rearrangements in myocardial cells and also decreases penetration of ionized calcium into cytoplasm.
Statement of Purpose
This study was undertaken in order to determine:
1.

What is the performance of isolated cardiac

muscle removed from SHR and WKY hearts?

Muscle mechanics

were evaluated (a) during acidosis and hypoxia at different
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extracellular calcium concentrations;

(b) after addition of

isoproterenol to the muscle, both in the presence and
absence of propranolol; and (c) in SHRs after chronic
antihypertensive therapy.
2.

Which drugs work effectively in chronically

decreasing blood pressure and which mode of administration
(that is, pump, drug in drinking water, or intraperitoneal
administration) is most effective?
3.

Does cardiac hypertrophy disappear after chronic

antihypertensive treatment?
Study Design
This study was subdivided into three major parts.
First, comparisons were made of the muscle mechanics
of SHRs and WKYs during acidosis and hypoxia at different
extracellular calcium concentrations.

Second, comparisons

were made of the responses of papillary muscle from SHRs
and WKYs to isoproterenol added both in the presence and in
the absence of propranolol.

Finally, an evaluation of

chronic antihypertensive therapy in SHRs was made in order
to determine which drugs work effectively and which mode of
administration is most effective.

Further, the animals

whose blood pressures were significantly lowered for 6 weeks
or longer were studied to see if hypertrophy disappeared and
how their papillary muscle responded to acidosis and
hypoxia.
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The central aim of this study was to determine if
SHRs respond differently from WKYs when extracellular
calcium is increased from 1.0mM Ca++ to 2.5mM Ca++ and then
made hypoxic.

It was also to see if chronically treated

rats respond more like the SHRs or WKYs.
Other investigators (Aoki et al., 1974; Hamrell and
Alpert, 1976; Heller, 1977; Limas and Cohn, 1977) have all
shown that the SHRs handle calcium differently from WKYs.
They showed that there is a decreased resequestration of
calcium by the sarcoplasmic reticulum of the SHRs.

Heller

(1978) showed that spontaneous after-contractions occur
more frequently and with greater amplitude following paired
pulse stimulations in SHRs than in WKYs.

Doca-treated rats

did not demonstrate exaggerated after-contractions when
compared to WKYs.

Taubert et al.

(1980) have demonstrated

that when extracellular calcium was increased during hypoxia,
the SHRs responded differently from WKYs.

Chapter 2
MATERIALS AND METHODS
All experiments were carried out on two types of
adult male rats (4-6 months of age) weighing 250 gms to 450
gms.

One type was the spontaneously hypertensive rat (SHR)

from the Okamoto-Aoki strain.

The second type was the age-

matched Wistar Kyoto (WKY) normotensive control.

SHRs and

WKYs were maintained and bred in the U.O.P. vivarium.

There

were about three to four rats per cage on commercial rat
chow and tap water.

Breeding was by brother-sister mating.

Rats were kept on 12 hours light-12 hours dark cycle.
Chronic Antihypertensive Treatment
The SHR population was divided into four groups,
each of which was subjected to a different chronic antihypertensive treatment.

SHRs that were chronically treated

are referred to as PRET (pretreated rats).
Group 1: Propranolol
Hydrochloride
Three male SHR rats (250-450 gms) were placed under
methohexital sodium anaesthesia (60 mg/kg i.v.) and an
ALZET osmotic minipump (model 2002, Alza Corporation, Palo
Alto, California) containing propranolol hydrochloride
(Sigma) dissolved in water was implanted subcutaneously in
the dorsal region via a small skin incision.
23

This pump
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provided a continuous infusion of 20 mg/kg/day.

Amount of

propranolol used was dependent on weight of the rat such
that it received 10 mg/kg/day.
the device was 0.55 u 1/hr.

The nominal pumping rate of

This guaranteed a constant flow

during at least 14 days in vivo in rat subcutaneous tissue
(product information, Alza Corporation).

At the end of the

fourteenth day of infusion, the minipumps were removed from
the animals and new minipumps implanted.

This procedure was

repeated for two subsequent 14-day periods.
In addition, rats in this group were given propranolol hydrochloride (Sigma) in their drinking water (60 mg/
liter).
Preliminary testing showed th at neither route was
effective in lowering blood pressure.
Group 2:

Alpha-Methyldopa
Five male SHRs were treated with alpha-methyldopa

(Merck, Sharp, and Dohme).

The rats were injected with

alpha-methyldopa (75 mg/kg i.p.) daily.

Powdered alpha-

methyldopa (5 gm/liter) was also added to their drinking
water.
Group 3: Clonidine
Hydrochloride
Thirteen SHR rats were given clonidine hydrochloride
(Boehringer Ingelheim)

(0.6 mg/ kg/day ) through ALZET osmotic

minipumps implanted subcutaneously in their dorsal regions.
The procedure was the same as that described for Group 1 •
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Eight of the 13 SHR rats were also given clonidine hydrochloride mixed in their drinking water (0.5 mg/50 cc).
Group 4:

Verapamil
Seven SHR rats were treated with verapamil (Knoll

Pharmaceutical).

The verapamil was dissolved in their

drinking water (40 mg/50 mL).

All the rats in the four

groups drank about 25-30 ml of water/day with or without
drugs in it and this was the same for SHRs and WKYs.
Blood Pressure Monitoring
Systolic blood pressure was measured in unanesthesized rats by the plethysmographic tail cuff method (Bunag,
1973; Williams, Harrison, and Grollman, 1939).

Prior to

measurement, each rat was restrained in a lucite container
connected to a temperature control unit (Narco Biosystems,
type MK IV) which was set at "5"
allowed to warm up

(40°C on warmer) and

10 or 15 minutes, for the purpose of

fo~

increasing blood flow in the tail (Rand, Burton, and Ing,
1965).

A pressure cuff (E & M Instrument Company) was

placed on the tail of the rat.

The bulb sensor was held

to the tail by tape approximately 3/8 inch wide, holding the
sensor in a partially deflated condition.

The pneumatic

pulse transducer was connected to an electrosphygmograph
(E & M Instrument Company, type ESG-300) which was, in turn,
connected to the pressure cuff and a desk model Physiograph
4-channel recorder (E

&

M Instrument Company, type D.t-1P-4A) .
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Figure 1.

Rat blood pressure monitoring

set up
Arrowhead indicates direction sig nals are
travelling.
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The cuff was inflated; upon release of the pressure, blood
flowed back into the tail.

This blood flow set up pulsa-

tio ns which could be picked up by the pneumatic bulb, which
transmitted it to the pneumatic pulse transducer.

The

signals from the pneumatic - pulse transducer passed through
an amplification unit (Narco Biosystems) in the Physiograph.
The unit was calibrated before each session of blood
pressure recordings by setting the deflection of the tracing
stylus to 2 . 5 em on the graph paper (Narco Biosystems) for
every 100 mmHg pressure.

A minimum of three pressure

measurements were taken on each rat, · at 2-minute intervals
in a room with quiet environment .
Papillary Muscle
Rats were anesthesized with sod ium pentobarbital
(30 mg/kg i.p.) and papillary muscles taken from the left
or right ventricles .

Hearts were diss e cted free and opened ,

and a suitable muscl e rapidly removed by clipping it free at
each end.

The muscles were mounted vertically between two

spring-loa ded clips , and a tension transducer (Statham UC
2) attached to the top clip.

The immobility of the clips

allowed the papillary muscles to contract isometrically .
The platform holding the top clip was connected to a micrometer, facilitating manual l e ngth adjustments.
A 20 ml volume bath containing a Krebs-Ringer
bicarbonate buffer solution was prepared.

A gas mixture
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Figure 2.

Papillary muscle bath
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of 95%

o2

co 2 was used to aerate
with co , a pH of 7.4 was
2

and 5%

equilibration

the solution.
recorded.

After

Tempera-

ture was maintained constant at 30°C by surrounding the bath
with a sleeve connected to a Haake circulating pump.

The

muscles were lowered into this bath and stimulated, at a
rate of 12/min., by a Grass stimulator (model S-88) with
platinum electrodes placed parallel to, but not touching,
the muscle.

Voltage used was threshold +20%, and duration

averaged 10 ms.
After a 1-hour stabilization period, Lmax (muscle
length at which maximal developed tension occurred) was set.
X Lmax for all muscles used in these studies was 4.68
0.229 mm.

±

Control measurements were then made and individual

experiments begun.

At the conclusion of the experiments,

the muscles were weighed and the cross-sectional areas
([muscle weight/muscle length]/[density of water])
2
0.99 ± 0.051 mm •

X CSA =

Measurements taken included resting

tension {RT), developed tension {DT), maximal rate of
tension development {+dT/dt), maximal rate of tension
decline {-dT/dt), time to peak tension (TPT), time to half
relaxation

{RT~ ),

and time to maximal relaxation {TPR).

All data except TPT,

RT ~ ,

and TPR were divided by cross-

sectional area for normalization of data.

The control

measurements taken refer to zero time immediately prior
to beginning of intervention.

Control values are taken to

be 100% and subsequent minutes show change of percentage.
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Individual Protocols
Addition of Isoproterenol Before
and After Propranolol
After muscles stabilized and control measurements
6
were taken, 10- M isoproterenol was added directly to the
bath via a microliter pipette.

Data were then collected for

15 minutes at 5-minute intervals.

At the end of this 15-

6
minute period, 10- M propranolol was added directly to the
bath via a microliter pipette.
10-minute period.

Data were collected over a

Following this the bath was washed

6
thoroughly and 10- M isoproterenol again added to the bath
and data taken at 1-minute, 5-minute, and 1+-minute intervals .
A total of 13 muscles were treated with propranolol
and 12 muscles treated with isoproterenol, while 14 muscles
were treated with only isoproterenol.
Acidosis and Change in
Extracellular Calcium
After the muscles stabilized in a buffer containing
1.0mM Ca++, control readings were taken.

Acidosis was

induced by changing the aerating gas mixture from 95%

o2

- 5%

co 2

to 85 %

o2

- 15 %

co 2 .

This lowered the pH of

the muscle bath from 7.4 to approximately 6.9.
ings were taken every 5 minutes for 1 hour.

The read-

At the end of

the hour, extracellular calcium was increased from 1 . 0 to
2.5mM Ca++ and maintained at this level for 30 minutes,
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which was sufficient time for peak inotropic effect to have
been reached.
Hypoxia and Reoxygenation
The muscle was made hypoxic while maintaining
acidosis and Ca
from 85%

o2

++

- 15%

lasted for 1 hour.

level of 2.5mM by changing the gas mixture

co 2

to 85% N

2

- 15%

co 2 .

The hypoxia

During this hour, data were collected.

At the end of this period, acidosis was terminated by
changing the gas mixture to 95%

o2

- 5%

co 2

(reoxygenation) .

Data were also collected at this point.
Statistics
Comparisons of blood pressure before and after
treatment were considered statistically significant at
p

2 0.05

level using the paired t-test.

Contractility

changes of the papillary muscle due to isoproterenol, propranolol, acidosis, hypoxia and reoxygenation were compared
using the paired t-test and were considered statistically
significant at p

~

0 .+5 level.

Comparisons among groups of

muscles were made using the groups t-test and a significance
of p _:: 0.05.

Data were compared using either the grouped or

the paired t-test, as appropriate, and results considered
significant at p

~

0. 05.

Chapter 3
RESULTS
Effectiveness of Various Methods
of Administration

The ALZET osmotic minipump was not effective with
all the drugs used.

Propranolol administered through t he

minipump resulted in variable results in the three rats
(see Table 1).

The mean blood pressure reading decreased

for a few weeks, then rose.
While clonidine administered through the ALZET
osmotic minipump did result in dec reased blood pressure,
all the rats with the clonidine pump died at some time
while being warmed for blood pressure monitoring.

Prior

to death, they were observed to be "frothing" from the
nose and mouth.

Autopsies revealed that these rats had

hemorrhage in their lungs.
Alpha-methyldopa could not be administered through
the minipump because the dose of alpha-methyldopa required
for the treatment of hypertension was too high to be
dissolved in the 228.0

~£

water used in the pump.

The pump

was not used with verapamil because verapamil was n ot
soluble enough in a carrier to be diluted to 228.0

~£ .

The amount of drugs was too large to be used in the pump.
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Table 1
Effect of Clonid ine, Alpha-Methyldopa, Verapamil and Propranolol on the
Blood P r ess ure of Spontaneous l y Hyper t e nsive Rats
Week of
Treatment

Drug
Clonidine

= 8)

Blood
Pressure
(mmHg)

Alpha methyldopa
(n = 8)

Blood
Pressure
(mmHg)

Ve rapamil

Blood
Pressure
(mmllg)

(n

(n

=

7)

Propran o l ol
(n

=
a
b
c

3)

n
n

=
=

Blood
Pressure
(mmHg

Mean

± SEM
Mean

:t

SEM

Mean

:t

SEM

Mean

± SEM

0

1

2

3

4

5

6

7

8

198 . 8

167.5

16 5.0

155 .0

155 . 7

140.0

14 8.0

156.7

160. 0a

155.0b

7.9

8.0

5.3

7. 1

3. 5

6.8

11.6

20.3

5.8

15 . 0

194.4

165.6

1 52. 4

153.8

166 .0

162 . 5

164 . 3

167.5

1 50 . 0b

4. 1

4.5

13.6

10 . 6

5.4

7 .5

10 . 9

11 . 1

10 . 0

180.0

168.6

159. 3

145 .7

150 . 0

14 7 . 1

142.9

3.8

9.4

6. 6

6.1

7.2

9 .9

9.4

18 8.3

160.0

16 3.3

160.0

158.3

1 83 . 3

173 .3

6.0

10.0

20 . 3

15. 3

10 . 9

14 . 5

20.3

140 . 0c 140.0c

9

10

11

12

120.0c

130.0c

180.0b

1 60.0b

160.0b

1 40 . 0b

10.0

20 .1

10 . 0

20.1

140.0c

1 40. 0c

160 . 0c

140. 0c

3
2

n

w
U1
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The osmotic minipump was a good vehicle for administration of some drugs because it maintained a constant
daily dose and it eliminated the problems involved in
handling the rat every day.

One drawback encountered was

the small capacity of the pump, which eliminated some drugs.
Drinking Water
Mixing the drugs in drinking water was effective for
some drugs but not for others.

Propranolol administered

only in the drinking water could not lower blood pressure
mor e than 10%.

Very little decrease in blood pressure was

obtained when alpha-methyldopa was mixed in the drinkin g
water.

On the other hand, both clonidine and verapamil

mixed in drinking water resulted in significant decreases
in blood pressure (see Figure 7).
Injection
Rats given alpha-methyldopa as an anti-hypertensive
treatment were the only subjects treated by intraparitoneal
injection.

This method of delivering the drug was effective,

but it increased the chances of infection.
Magnitude of Blood Pressure Decrease
As shown in Table 1 and Figure 3, only one of the
three rats treated with propranolol evidenced decreased
blood pressure.

In this rat, propranolol (administered

through a combination of pump and drinking water) caused a

37 .

Figure 3. The effect of propranolol on blood
pressure of spontaneously hypertensi ve rats (n = 3)
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22.2% decrease in blood pressure at the end of 12 weeks of
treatment.

In the other two rats, blood pressures fluctu-

ated during the chronic treatment and they died by the end
of the sixth week.
Table 1 and Figure 4 show the effects of clonidine
(administered in drinking water), Table 1 and Figure 5 show
the effects of alpha-methyldopa (administered through
injection and drinking water) and Table 1 and Figure 6 show
the effects of veraparni l

(in drinking water) on the b lood

pressures of spontaneously hypertensive rats.

The eight

rats treated with clonidine displayed a 25.5% decrease in
blood pressure at the e nd of the s ixth week.

Five of these

rats were used for papillary muscle studies at the end of
the seventh week and the two died later.
Alpha-methyldopa caused a 15.5% decrease in blood
pressure in the rats at the end of the sixth week.

Two rats

on the alpha-methyldopa till the twelfth week showed a 28 %
decrease in blood pressure, as seen in Figure 5.

Three

rats died by the end of the seventh week.
Veraparnil treatment resulted in a 20.6% decrease in
blood pressure in all seven rats by the sixth week and was
terminated here.

Four of the rats were used for studies.

Treatment with clonidine, with alpha-methyldopa ,
and with veraparnil yielded significant decreases in blood
pressure by the end of the sixth week (Figure 7).
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Figure 4.

This figure shows the mean va lues

(± standard error) of the blood pressure resulting
from the chronic treatment of SHRs with clonidine
(n = 8)
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Figure 5. This figure shows the mean values
(± standard error) of blood pressure resulting from
the antihypertensive effect of chronic treatment by
alpha-methyldopa on spontaneously hypertensive rats
(n = 5)
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Figure 6. This figure shows the mean values
standard error) of blood pressure resulting from
antihypertensive effect of chronic treatment by
verapamil on spontaneously hypertensive rats (n = 7)
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Figure 7. Mean blood pressure readings of
spontaneously hypertensive rats before and after
treatment ·
p values are results of paired students t-test
comparing blood pressures in the same rat before and
after 6 weeks of antihypertensive treatment.
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Effect of Chronic Antihypertensive
Treatment on Hypertrophy
Table 2 shows the heart to body ratios of SHR, WKY
and pretreated rats.

The heart to body weight ratio was

significantly greater in the SHR than WKY (p < 0.01).

Over-

all, the heart to body ratio of the rats that were chronically treated with antihypertensives was 3.37 ~ 0.26.
Papillary Muscle Studies
In the papillary muscle studies the mean control
data for all SHRs RT = 1.01; DT = 2.97; +dT/dt = 34 .2; -dT/dt=
20.4; TPT = 172.9;

RT~

= 101.3 and TPR = 279.7 were equal to

those for the WKYs, RT = 0.84; DT = 2 .88; +dT/dt = 34.5;
-dT/dt = 20.5; TPT

=

152.8;

RT~

= 96.3; and TPR = 273.

Response to Isoproterenol
in Presence or Absence
of Propranolol
One part of the study examined the effect of isopro6
terenol (10- 6 mM) in the absence of propranolol (10- mM) on
cardiac muscle mechanics.

Table 3 shows normalized data,

while Table 4 expresses that data as percentage of control.
One minute after isoproterenol addition, developed tension
was significantly lower than control for both SHR (p < 0. 01)
by 0.49 and WKY (p< 0.05) by 0.42.

After 10 minutes, only

the SHR was significantly lower than control (p < 0.05) by
0.14.

A significant decrease was seen 15 minutes after

Table 2
Heart to Body Ratios of SHR, WKY, and Pretreated Rats

Experimental
Group

n

Body wt. (gm)

WKY

7

352.2

±

SHR

7

364.7

PRET (Clonidine)

2

PRET (Verapamil)
PRET (Propranolol)

Heart wt. (gm)

Ratio (X1o-3)

23.0

0.878 ~ 0 .067

2 . 50

±

0 . 11 ·k

±

30.6

1.269

± 0.143

3.44

±

0 .1 2*

302.4

±

7.5

1.048

±

0.172

3.45 :t 0.48

2

267.2

±

67.9

0.809

:!:

0 .050

3 . 19

1

223.3

0 .795

±

0 . 62

3 .56

Data are mean +
- standard error
;';p

< 0. 01

,j::.

1.0

Table 3
The Effec ts of Isoproterenol on Papillary Muscle Mechanics

Resting
Tension
(g/mm2)

Developed
Tension
(gjmm2)

Maximal Rate
of Tension
Development
(gjmm2sec)

Maximal Rate
of Tension
Decline
(g/mm2sec)

Time to
Peak Tension
(msec)

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

Time
(min)

Rat.
Type

CONTROL

WI<Y

0 . 95 + 0 . 09

3 . 66 + 0.45

45.80 +

5.62

27.64 + 3.19

156 . 67 + 3.54

SHR

1.14 + 0.13

4 . 59 + 0.89

54.68 + 10.02

29 . 36 + 4.57

172. 50 + 2. 50

WKY

0.92 + 0 . 09

3 . 24 + 0.43** 46 . 26 +

-

6.47

25 . 54 + 3 . 69

145.63 + 3.19

93 . 13 +

SHR

1.14 + 0.13

4.10 -+ 0.81** 54.50 -+

9.59

26.03 + 3 . 88

162.50 + 5.28

90 . 00 -+ 11.03 351 . 67 -+ 15 . 63

WKY

0.94 + 0.09

3.60 + 0.44

48.47 +

5.52

27.94 + 3.34

147 . 78 + 2 . 90

86.67 +

3 . 91 307.7 8 +

SHR

1.12 + 0.13

4.41 + 0.86

56.20 +

9.96

29 . 64 + 4 . 60

161.67 + 5.27

93.33 +

6.01 337.50 + 17 . 97

WI<Y

0.94 + 0.09

3 . 52 + 0.43

46 . 84 +

5.50

28 . 70 + 3 . 83

147 . 78 + 2 . 90

86.11 +

5 . 39 308.33 + 11.02

SHR

1. 10 + 0 . 13

4 . 45 + 0.88** 54 . 58 +

-

9.88

30 . 15 + 4.65

162.50 + 4 . 23

96.67 +

7.82 330.83 + 14.16

WKY

0.97 + 0.11

3.31 + 0 . 41*

44.39 +

5.48

27.36 + 3.61

150.00 + 2.76

84.44 +

5.68 296.88 + 15 . 97*

SHR

1.10 + 0.13

4.00 + 0 . 82** 51.13 +

9.35 **29.51 + 4 . 54

167 . 50 + 3 . 82

89.17 +

6.51 326 . 67 + 10.14

1

5

10

15

Data are mean
(SHR, n

=

>'< p < 0. 01
>h'<p < 0.05

!

-

-

-

-

94 . 44 +

3.67 336.67 + 11 . 96

104.17 + 10.03 354.17 + 15.02

-

-

3.12 331.25

±.

6.25

6 . 88

standard error

6; WKY, n

=

8)
l1l

0

Table 4
Percentage of Control Data of Papil l a r y Muscle Mechanics Due to Addition of Isoproterenol

Time
(min)
1

5

10

15

Resting
Tension
(g/mm2)

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Development
(g/mm2sec)

Maximal Rate
of Tension
Decline
(gj mm2sec)

Time to
Peak Tension
(msec)

WKY

99 . 10 + 0.9

93.51 + 1.9

103 . 06 + 2 . 4

94 .1 4 + 3 . 8

93 . 2 + 1. 3

100.0 + 3.3

101.4 + 3 . 3

SHR

1 00.00 + 0 . 0

89.82 + 1.7

100.72 + 1. 6

88.83 + 2.3

94 . 2 + 2.7

85.8 + 5 . 3

99.6 + 3.5

WKY

99 . 01 + 2 . 0

98.30 + 1.4

109.42 + 5.2

101.70 + 2.8

94.5 + 1.7

93.3 + 3.6

91.8 + 1.7

SHR

98 . 22 + 1. a

96 . 88 + 1.9

103 . 70 + 2 . 2

100 . 88 + 2 . 3

93 . 7 + 2 . 7

91.3 + 4.1

95 . 8 + 5 . 2

WKY

99 . 01 + 2.0

96 . 47 + 1.8

104.82 + 4 . 7

102.68 + 3 . 3

94 . 5 + 2 . 0

93 . 0 + 3 . 7

92.0 + 2.9

SHR

96 . 80 + 2 . 0

96 . 35 + 1.8

100 . 35 + 2.1

102.82 + 1.3

94.3 + 2 . 7

94.0 + 3.8

93.7 + 3.2

WKY

101.57 + 2.6

89.73 + 1.3

97 . 24 + 2 . 8

96.45 + 2.4

95.4 + 1.9

89.1 + 4 . 4

88 . 3 + 2.8

SHR

96 . 80 + 2.0

87 . 52 + 3.8

93 . 57 + 1.4

100.82 + 1.6

97 . 2 + 2 . 5

97 . 2 + 4 . 4

92 . 7 + 2 . 8

Rat.
Type

Data are mean
(SHR, n

=

±

Time to Half
Relaxation
(msec)

Time to
Max i mal
Relaxation
(msec)

standard error

6 ; WKY, n

=

8)

\•.Tl
--"
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addition of isoproterenol in both SHR (p < 0.05) by 0. 59
and WKY ( p < 0. 01 ) by 0. 3 5 •
The second part of the study examined the effect of
6
the addition of 10- mM isoproterenol in the presence of
10- 6 mM propranolol.

Table 7 shows the mean normalized data

and Table 8 gives the percent of control of the normalized
data of papillary muscle mechanics in response to
isoproterenol added 10 minutes after the addition of
propranolol.

One minute following the addition of isopro-

terenol, DT, +dT/dt and -dT/dt of the WKY were significantly
higher than control (p <0.05) by 0.18, 1.31, and 1.03
respectively.

After 5 minutes, the +dT/dt of the WKY was

significantly higher than control (p < 0.05) by 1. 60 and the
-dT/dt of the WKY was significantly higher than control
(p < 0.01) by 1. 55.

Only the -dT/dt of WKY was signifi-

cantly higher than control (p < 0.05) by 1 .16 after 10
minutes.
Response to Propranolol
Normalized data (Table 5) show that 1 minute after
the addition of propranolol (10-

6

rnM)

the DT of WKY and the

SHR were significantly lower than the control (p < 0.05) by
0.06 (WKY) and 0.09 (SHR).

After 5 minutes, the DT of the

WKY and SHR, the +dT/dt of only WKY, the -dT/dt of both
WKY and SHR and the TPR of only SHR were significantly
lower than control (p < 0.05) but 10 minutes after propranolol

Table 5
The Effects of Propranolol on Papillary Muscle Mechanics

Time
(min)

Resting
Tension
(g/mm2)

Rat.
Type

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Develofment
(g/mm sec)

Maximal Rate
of Tension
Decline
(g/mm2sec)

Time t o
Peak Tension
(msec)

WKY

o. 60

±

0.11

1. 50

± 0. 36

15.48

± 3.73

10.30 ± 2.13

140.83

' sHR

0 . 85

±

0.11

2.18

± 0.33

25.76

±

16.25:!: 2.18

148.75:

WKY

0. 60 : 0.10

1.44: 0 . 34**

14.68

± 3 .43

SHR

0.85:!: 0.11

2.09

± 0.32**

25.31

±

3.82

WKY

0.59: 0.10

1.19

±

13 .85

±

3.31**

SHR

0.84: 0.11

1 .97:!: o.3o**

WKY

0. 57 : 0.10

0.91

±

0.19

12.55

±

3.00'b'<

SHR

0.86

±

1.69

±

0.35**

21.27

±

4.32

Control

5

10

Data are mean
(SHR,

n

=

8;

±

0.12

0.67**

3.79

24.11 :!: 3.88

9. 80 :

2.10

± 13.56
4.88

146.67 :!: 20.91

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

90.83

±

88 . 12

± 6 . 61

213.75

±

17.71

80.00 :!: 8.46

210.83

±

31.12

213.12

±

10.68

±
±

26.13

6.11

224.17! 28.52

± 2.10

140.00

±

10.30

97.50! 4.12

9.18

±

1.96**

150.00

±

25.06

85.83

±

8.60

215.00

15.34

±

2.09**

148.12

±

1.31

88.75

±

3.63

193.12

7.88

±

1 .5 8**

155 .00

±

22.58

80.83

8.31

143.33 !

so ±

1•64

82.50

±
±

7.07

180.6 3

16.16

12.99 ± 2.43

14 7 •

±

10.08+-'<
33.20
11. 66>'<

standard error

WKY,

n

=

6)

>'<p < 0.0 1
< 0 .05

1d<p

Ul

w

Table 6
Percentage of Control Data of Papillary Muscle Mechanics Due to Addition of Propranolol

Time
(min)

5

10

Maximal Rate
of Tension
Decline
(g/mm2sec)

Time to
Peak Te nsion
(msec)

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

1. 6

95.0 :

5.0

102.7 ± 6.7

87.3 : 4.6

94.1 :!: 5.4

96.6 :!: 1.2

98.2:!: 1.3

99.6 ::!:

3.8

101.3 :!: 4.55

79.7:!: 3.8

90.7:!: 2 . 4

88 .1 +

4.5

104 . 4 : 9.3

SHR

98.9 :!: 1.10

91.9::!: 2.8

90.4

4.9

93.2 ::!:

3.2

100.3 :!: 3.3

103.2

±

6.0

91 . 9 :!: 3. 2

WKY

97.7:!: 3.4

72.8 :!: 6.2

80.7:!: 2.4

77 . 4 :!:

4.3

109.3 :!: 8.4

88.8

±

5.6

92.4 :!: 5. 3

SHR

99.8 : 1 . 5

74 . 4 :!: 9.0

79.5

±

10.7

93.3:!: 4.1

85.4 :!: 2.8

Maximal Rate
of Tension
De ve l of.men t
(g/nun sec)

Rat .
Type

Resting
Tension
(g/nun2)

Developed
Tension
(g/nun2)

WKY

103 . 0 ±" 1 .9

96.7 ± 1.1

96.1

SHR

98.9: 1.1

WKY

±

±

±

9.6

77.3

93.3

99 . 7

±

±

5.2

2.5

±

7.2

102.6 + 6.9

94.5 :!: 5.9

97 .0 :!: 6.7

113.7

Data are mean ± standard error
(SHR, n

=

8; WKY , n

=

6)

U1

""'

Table 7
Mean Values of the Effects of Isoproterenol on Papillary Muscle
Mechanics After Addition of Propranolol

Developed
Tension
(gjmm2)

Maximal R;;~te
of Tension
Develof.ment
(g/mm sec)

Maximal Rate
of Tension
Decline
(g/mm2sec)

Time to
Maximal
Relaxation
(msec)

Time
(min)

Rat.
Type

Resting
Tension
(g/mm2)

Control

WKY

0.56: 0 . 11

0.96 ± 0.18

12.07:!: 3.15

7.77:!: 1.63

150.83 :

20.91

77. so :!:

8 . 34

216.67 : 26.38

SHR

0.96 ± 0.13

1.94 :!: 0.38

24.54 :!: 4.63

14.59 :!: 2.49

148.33 :

1. 67

84.17:

7.57

184.17:!: 13.56

WKY

0 . 54:!: 0 . 11

1.14:!: 0 . 23'"'''

13 . 38:!: 3.24>'d<

:t

10 .33

209.17:!: 19.46

SHR

0.94:!: 0 . 12

1. 96 :!:

1. 67

84.17:!:

6.38

175.83 :!:

WKY

0. 52: 0.09

1.23:!: 0.30

143.33: 18.95

91.17:

9. 19

213.33 :!: 44.07

SHR

0.91 ! 0. 1 2

1.92

0.35

24.65 :!: 4.65

141.67 :

4. 01

81.67 :!:

3.80

176.67:!: 14.24

WKY

0 . 53 : 0.10

1. 11 :!: 0. 28

12.72: 3.17

8 . 9 3 ± 1 . 80 * ''< 1 4 4 . 1 7 :!: 1 7 . 8 1

85 . 83 :!:

6.88

198.33:!: 21.47

SHR

0 .92 ± 0.12

2.01 :!: 0. 26

25.97 ± 3.70

83.33 :!:

3.80

183. 33 ! 13.01

5

10

:t

o. 30

24.82 :!: 3 .9
13.67: 3.46>'<>'<

Time to
Peak Tension
(msec)

8 . 80 :!: 1 . 8 1 >'<>'< 1 4 6 . 6 7 :!: 1 9 . 1 7
14.99 :!: 1.68
9.32:!: 1.99"'
14 . 53 :!: 3.00

16.78:!: 1.71

148.33 :!:

145.83 :!:

3.74

Time to Half
Relaxation
(msec)

90.00

8.20

Data are mean ± standard error
(SHR, n

=

6; WKY, n

=

6)

'~P < 0.01
,.,,.,p < 0.05

U'1
U'1

Table 8
Percentage of Control Data for the Effects of Isoprote renol Af te r Addition
of Proprano l o l o n Papillary Muscle Mechanics

Time
(m in)

5

10

Resti ng
Tension
(g /mm2)

Rat.
Type

Developed
Tension
(g j mm2)

WKY

96.6

±

2.2

117.8:!:

6.4

SHR

98 .9

±

1.1

11 3. 1

±

1 7. 5

WKY

94 . 9

:!:

2. 3

122.4

:!:

9.5

SHR

95.8

±

1.9

10 1 .9

:!:

3.8

WKY

96 .3

:!:

2. 4

108. 1

:t

11.21

SHR

95.8:!: 1 .9

12 5 .5

:!: 31 . 0

Data are mean
(SHR, n

=

±

Maximal Rate
of Tension
Deve l of.ment
(g/mm sec)

Maxima l Rate
o f Tension
Decline
(g / mm2sec)

11 6 . 7 :!:

7. 8

11 4. 1 +
-

±

8.7

117. 8 :!: 21.5

111 . 8::

3.9

121.9

99 . 7

±

3.2

91.6

104.9

:!:

5.2

117 . 1

:!: 16. 8

107.0

:!:

3.4

:!: 12.8

11 5 . 1 +
1 35 . 3

3 .4

4.9

:!: 28.3

Time to
Peak Tension
(msec)
97 . 7

±

4.1

Time to Ha l f
Relaxatio n
(msec)

T ime to
Max imal
Re l axation
(msec)

117 . 6 ::

8. 1

98. 1

:!:

3.2

"4. 4

97.6

:!:

7. 1

95.7 :!:

9.3

±

6.0

93.3 ::

6 .5

100. 1 :: 1. 8

1 0 1. 4

:!:

95.2:!: 2.7

12 2.9

:!: 15 . 9

95.6

:!: 3.3

96.3 :: 2 . 3
98 .4

:!: 3.0

100 . 5:!:

8.5

11 6.7 :!: 16.7
104.7

:t

9.6

97.8

102.7

:!: 11. 5

standard error

6; WKY, n

=

6)

V1
C'\
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was added to the bath, the developed tension of SHR was
significantly lower than the control (p < 0.05) by

o. 49,

while the rate of tension development and -dT/dt of WKY
were significantly lower than control (p < 0. 05) by 2. 9 3
and 2.42 respectively.

The data show that only the time

to peak relaxation of SHR was significantly lower than the
control p(0.01) by 33.12 after 10 minutes of intervention.
In Table 6 the data in Table 5 are expressed as
percentages of control.

The table shows that 5 minutes

after propranolol addition the developed tension of WKY
was significantly lower th an that of the SHR p(0.05) by
12.2%.
Response to Acidosis and
Increase Extracellular
Calcium (n = 21)
In the first part of this protocol, muscles were
subjected to acidosis for 1 hour.

At the end of the hour,

contractility of all groups of papillary muscles was
significantly depressed when compared to their pre- acidotic
controls (Figures 8 and 9).

After 30 minutes of acidosis,

contractility decreased by 29.0% (p < 0. 05) for the WKY,
while for the SHR it remained the same as that of the
control.

After 60 minutes , SHR was significantly higher

than WKY by 21% (p < 0.01)

(Figure 9).

Table 9 shows the

normalized data of the effect of acidosis on papillary
muscle mechanics while Table 10 expresses this data as
percent control.

Control data are mean parameters of

53

Figure 8. Effects of Acidosis, increased calcium,
hypoxia and reoxygenation on the developed ten~ion of
papillary muscles (SHR, n = 7; WKY = 7; PRET, n = 7)
p values are results of grouped t-t est comparing
SHR, WKY and PRET.
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Figure 9. Effects of Acidosis, increased calcium,
hypoxia and reoxygenation on the maximum rate of tension
development of papillary muscles (SHR, n = 7; WKY, n = 7;
PRET, n = 7)
p values are results of grouped t-test comparing
SHR, WKY and PRET.
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Table 9
The Effects of Acidosis on Papillary Muscle Mechanics

Resting
Tension
(gjmm2)

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Development
(g/mm2sec)

Maximal Rate
of Tension
Decline
(g/mm2sec)

Time to
Peak Tension
(msec)

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

Time
(min)

Rat.
Type

CONTROL

WKY

0.82 + 0.11

2.84 + 0.47

34.66 + 5.72

18.59 + 2.88

159.29 + 8.04

104.29 + 8.88

244.29 + 27.78

SHR

0.95 + 0.13

2.16 + 0.52

21.90 + 4.86

15.09 + 3.70

194.29 + 2.65

110.00 + 9.92

272.14 + 18.71

PRET

0.91 + 0.05

2.52 + 0.53

29.13 + 7.05

18.81 + 3.71

174.1 3 + 2 .57

93.34 + 2.57

225.56 +

WKY

0 .76 + 0.11

2.44 + 0.38

30.61 + 4.17

17.53 + 2.43

158.57 + 4.03

96.43 + 6.42

225.00 + 14.49

SHR

0.81 + 0.12

1.83 + 0.34

18.36 + 3.48

12.57 + 2.42

187.86 + 5.32

113.57 + 9.22

262.14 + 22.24

PRET

0.77 + 0.04

1.91 + 0.40*

21.29 + 4.98** 14 .27 + 2.62

173.16 + 5.39

89.93 + 6.02

220.34 + 13.53

WKY

0.73 + 0.11

2.05 + 0.49*

25.74 + 5.89*

13.83 + 2.27

159. 29 + 4.42

92.86 + 8.43

221.43 + 19.33

SHR

0.70 + 0.11

1.88 + 0.37

20.50 + 3.73

14.67 + 2.62

175.71 + 5.27

89.29 + 6.48

225.00 + 15 . 17

PRET

0.73 + 0.05

2 .0 9 + 0.42** 23.83 + 5.03

16.03 + 2 .78

168.81 + 6.68

84.27 + 4.65

212.87 + 19.74

WKY

0.69 + 0.10

1.92 + 0.50*

13.40 + 2.27

146.43 + 8.28

95.71 + 8.04

227.14 + 21 . 76

SHR

0.67 + 0.11

1.60 + 0.33** 18.84 + 3.98** 13.69 + 2.54

157.14 + 5.95

93.57 + 6.23

220.00 +

PRET

0.67 + 0.05

1 . 84 + 0.54*

161.04 + 4.95

79.16 + 4.95

196.84 + 18.84

5

30

60

Data are mean + standnrd error
(SHR, n = 7; WKY, n = 7; PRET , n
>'<p < 0. 01
>'<>'<p

< 0. OS

=

7)

23.77 + 5 . 26*

21 .89 + 6.69

14.73 + 3.53

7 .37

8 . 71

0"\

t-->

Table 10
Percentage of Control Data f or the Effects of Acidosis on Papillary Mus c·le Mechanics

Time
(min)
5

30

60

Rat.
Type

Resting
Tension
(g/mm2)

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Development
(g/mm2sec)

Maximal Rate
of Tension
(g/mm sec)

Time to
Peak Tension
(msec)

Dec~ine

Time to Ha lf
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

WKY

93.6 + 3.1

87.9 +

6. 5

93.1 +

9. 8

96 . 6 +

8.1

100 .5 + 3.4

94.3 + 5 . 4

96 . 6 + 7 . 9

SHR

82.8 + 5 . 7

91.2 + 10.7

87 . 9 +

7.7

90 . 2 +

8.4

96.9 + 2.1

104.6 + 5 . 6

96.1 + 4 . 2

PRET

84 .1 + 1.7

76.7 +

4. 5

74.4 +

5.0

76 . 8 +

4.9

99.6 + 2.1

96 . 0 + 4.0

97 . 5 + 4 . 2

WKY

88.4 + 4.4

69.4 +

5.9

71.2 +

4.8

76.1 +

6 .4

101.2 + 4 . 7

88 . 8 + 4 . 9

93 . 5 + 5.2

SHR

72 . 4 + 4.5

93.0 + 10.0

108.5 + 14. 0

91.0 + 3.9

84 . 2 + 7 . 6

84 .1 + 6 . 3

PRET

79 . 3 + 2.4

84.6 +

4.9

85 .9 +

4.7

87.8 +

2. 6

97.1 + 2.8

90.0 + 2 . 9

92 . 0 + 5.9

WKY

85.6 + 6.0

63.2 +

6.7

65.9 +

5. 2

73.6 +

7.6

94 . 2 + 7.7

93.9 + 4.2

94.8 + 4.7

SHR

67 . 7 + 4.9

76 . 5 +

4.8

86.9 +

4. 4

97 . 1 +

7. 5

81.6 + 4.7

88 . 3 + 7.3

83.5 + 7.4

PRET

73 . 5 + 2 . 9

66.8 +

6.9

68.9 +

7.1

74.7 +

5.2

93 . 7 + 2 . 6

85 . 1 + 5.4

84 .8 + 6 . 2

100 .3 + 10.3

Data are mean + standard error
(SHR , n = 7; WKY, n = 7; PRET, n = 7)
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contr actility in each group of rats prior to any intervention .

Contractility of pretreated rats decreased

significantl y from control after 5 minutes of acidosis by
7 . 84 (p < 0 . 05) and that of WKY decreased significantly from
control after 30 minutes by 8 . 92 (p < 0 . 0 1 ) .

No significant

change was observed between SHR and i t s control.
A positive inotropic effect was found to result
from the changi ng of extracellular calcium from 1 . 0mM Ca++
++
to 2 . 5mM Ca
in the muscle bath during acidosis (Figures 8
and 9) •

During this intervention , no significant differ-

ence was observed in WKY , SHR or pretreated r ats studied.
The nor malized data of each group of rats were compared to
that o f its own control to d e t e rmine the e ff e cts of
increase e xtr a cellular Ca++ on muscle mechanics (Table 11) .
Significant increases in de v e loped t e nsion and rate o f
tension deve lopment were noted for the three groups o f
rats at 5, 1 5, and 30 minute s of this interve ntion .
Table 12 expresses the normalized data as p e rce nt c ontrol .
Re sponse to Hypoxia During
Acidosis and Reoxyge nation
at Normal pH
In this part of the proto col , muscle s in 2 . 5mM
Ca++ were made acidic and then reoxygenated a t normal pH.
Hypoxia at acidic pH cause d profound depression of muscle
contraction .

However, muscles reapproximate d pre hypo xic

v a lues after reoxygenation.

Table 13 presents the

normalized data of the hypoxic inte r vention , while Ta b l e 14

Table 11
The Effects o f Increase Extracellular CA++ Fro m 1.0mM Ca++ to 2.5mM Ca++

Resting
Tension
(gj mm2)

Deve loped

Maximal Rate
of Tension
Development
(gj mm2sec)

Maximal Rate
of Tensi o n
Decline
(gj mm2sec)

Time to
Pea k Tension
(msec}

Time to Half
Re lax ati on
(ms e c}

Time t o
Ma ximal
Re laxa tio n
(ms e c}

Time
(min)

Rat.
Type

CONTROL

WKY

0.69 + 0 . 10

1.92 + 0.52

23.77 + 5.26

13 . 40 + 2.27

146.43 + 8.28

95.71 +

8 . 04 227 . 14 + 21.76

SHR

0.70 + 0 . 11

1.60 + 0.33

18.73 + 3.99

13.57 + 2.57

159 . 29 + 6.48

93.57 +

6.23 224.29 + 11.40

PRET

0.67 + 0 . 05

1.84 + 0.54

21.89 + 6 . 69

14.7 3 + 3.53

161 . 04 + 4.95

79.16 +

4 . 95 1 9 3.16 + 18.04

WKY

0 . 75 + 0.12

2.71 + 0.56**

32.04 + 5 . 79*

16.86 + 2.52

157.14 + 4.85

107 . 14 +

8 . 07 "247.14 + 1 9 .90

SHR

0.69 + 0.13

2 . 26 + 0.44*

24.91 + 4.45*

16 . 34 + 2 . 73

166.43 + 8 .13

97.14 +

7 . 21 251.43 + 33.30

PRET

0.69 + 0.05

2.48 + 0.61*

29.00 + 7 . 39*

17.29 + 3 . 28

157.77 + 4.6 2

88.71 +

9.21 216.60 + 25 . 09

WKY

0.77+0.10

2.61 + 0.63**

32.31 + 6.70*

17.70 + 3.16

135.00 +10.78

85.71 + 10.42 217.14 + 26.79

SHR

0.67 + 0.12

2 . 03 + 0.38*

23.43 + 4.23*

15.01 + 2.29

164.29 + 8 . 40

93 . 57 +

5 . 42 232.14 + 16.52

PRET

0.66 + 0.05

2.41 + 0.55*

30.10 + 7.13*

16 . 70 + 2.87

156.44 + 5.05

86 . 46 +

7.09 214.93 + 25.2 2

WKY

0.73 + 0.11

2 . 68 + 0.65**

32.49 + 6.93*

17.90 + 3.24

152 . 14 + 1.84

93 . 57 + 10.49 251 . 43 + 22 . 05

SHR

0.66 + 0.13

1. 8 3 + 0 . 32

22.33 + 4.02** 14.56 + 2.48

160 . 71 + 6.01

9 2. 86 +

6. 52 21 3 .57 + 24.55

PRET

0 . 65 + 0.04

2 .36 + 0.50*

28.90 + 6.63*

155. 1 4 + 5. 33

87 . 13 +

6.13 213.53 +

5

15

30

Tensi ~n

(g/ mm )

Data are mea n + standa rd error
(SHR, n = 7; WKY, n = 7; PRET, n = 7)
*p < 0 . 01; **p < 0 . 05

16 . 81 + 2.75

2 .65

0"\
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Table 12
Percentag e of Control Data of Papillar¥ Muscle Mechanics Due to Increase
Calcium F rom l.OmM Ca +to 2. 5mM ca++ During Acidosis

Time
(min)
5

15

30

Re s ting
Tension
(gj mm2)

Rat .
Type

Developed
Tension
(g/ mm2)

E x trace~l u lar

Maximal Rate
of Tensio n
Development
(gj mm2 s ec)

Max imal Rate
of Tension
Decline
(g/ mm 2 sec)

Time to
Peak Tension
(msec)

Time to Half
Relaxatio n
(msec )

Time to
Maximal
Relaxa tion
(msec)

WKY

108.9 + 5 . 0

151.0 + 13.1

139.9 + 10.5

127.6 +

8.6

108 . 9 +

5. 4

112 . 7 + 4 . 5

110.2 +

SHR

98 . 4 + 5.6

142 . 2 + 10.3

137.5 +

122.9 +

7.9

106 . 2 +

5.0

104.5 + 6 .1

110.5 + 51.6

PRET

102.8 + 2.7

143.2 + 10 . 7

146 . 4 + 14.7

127.3 + 11.8

97 . 3 +

2.9

111.9 + 8.6

111.8+

5.7

WKY

115.2 + 8.8

138 . 1 + 15.6

137.5 + 15.4

129 . 0 + 13.0

94.9 + 11.5

90 . 0 + 8.2

98.5 +

9.9

SHR

99.6 + 2.7

129.0 +

127.7 +

113.3 +

7.0

PRET

100 . 0 + 0.0

142 . 7 + 13 . 2

WKY

109.6 + 9.5

SHR
PRET

9.0

5.6

5. 7

104.9 +

5. 5

100 . 9 + 4.5

106.0 +

152.4 + 18 . 0

125 . 9 + 14.2

97.3 +

2.4

109.1 + 5 . 9

110.2 + . 5 . 2

1 43 . 6 + 19 . 1

139.8 + 18 . 2

130.8 + 12.0

1 05 . 9 +

6.4

97.1 + 6 . 4

94.3 + 6.0

113 . 1 +

119.4 +

107.0 +

4.0

103.3 +

6.2

99 . 5 + 4.6

96.6 + 2 . 2

145.4 + 14.7

128.6 + 14.4

9 6.6 +

3.1

110.4 + 5 . 1

4.8

6.8

4. 0

7.5

151.6 + 20.1

112.0 +

5.5

98.0 + 11.4
109 . 7 +

5.2

Data are me an + standa rd error
(SHR, n

=

7; WKY, n

=

7; PRET, n

=

7)

C"l
C"l

Table 13
The Effects of Hypoxia on Papi l lary Muscles Exposed to 2.5mM Ca

Resting
Tension
(g/mm2)

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Development
(g/mm2sec)

Maximal Rate
of Tension
(g/mm sec)

Time to
Peak Tension
(msec)

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

Time
(min)

Rat.
Type

CONTROL

WKY

0.73 + 0 . 11

2.68 + 0.65

32.49 + 6.93

17 . 90 + 3.24

152 . 14 + 1.84

93 . 57 + 1 0.49 251 . 43 + 22 . 05

SHR

0.66 + 0.13

1.83 + 0.32

22.33 + 4.02

14.56 + 2.48

1 60.71 + 6.01

92.86 +

6 . 52 213.57 + 24.55

PRET

0 . 65 + 0.04

2.36 + 0.50

28.90 + 6.63

16 . 81 + 2.75

155.14 + 5 . 33

87 . 13 +

6 . 13 213.53 + 26.28

WKY

0 . 77 + 0.11

2 . 24 + 0.58

26 . 40 + 5 . 77** 15 . 04 + 2 . 68

145.71 + 4 . 42

88.57 + 10.88 226 . 43 + 19 . 33

SHR

0.74 + 0.15

1 . 16 + 0.17** 13 . 73 + 2. 1 7**

9 . 26 + 0.99

154.29 + 6.84

98.57 +

4.45 242 . 86 + 1 0.72

PRET

0. 72 + 0.06

1 . 43 + 0 . 25** 18 . 13 + 3.68** 10 . 94 + 1 . 50

146 . 56 + 7.23

84.31 +

8.99 210.70 + 23.59

WKY

0.77 + 0.09

0.91 + 0. 1 8** 1 2.61 + 2.72**

7.90 + 1.57

142.14 + 4.06

83.57 +

6.95 243 . 57 + 21 . 94

SHR

0.78 + 0 . 18

0.63 + 0.06*

7.30 + 0.90*

5 . 79 + 0.67

147 . 14 + 5.54

92 . 14 +

4 . 20 202.86 + 16.87

PRET

0.87 + 0 . 05

0.68 + 0.11 *

8. 39 + 1. 59*

6.10 + 0.62

132 . 19 + 5 . 13

80 . 47 +

9.76 224.07 + 15.37

WKY

0.81 + 0.11

0.87 + 0.18** 10 . 84 + 2 . 07*

8.1 7 + 1.61

139.29 + 5 . 04

80 . 71 +

5.16 206 . 43 + 22 . 3 2

SHR

0 . 75 + 0.17

0.60 + 0.10*

6.81 + 0.93*

5 . 73 + 0 . 71

152 . 14 + 6.88

85 . 00 +

7.23 207 . 14 + 14 . 36

PRET

0 . 87 + 0.05 >';

0 . 65 + 0.09*

8.19 + 1.42*

6.31 + 0.72

138.66 + 4 . 2 9

91.97 +

4 . 86 197.50 + 16 . 90

5

30

60

Data are me an + sta ndard error
(SHR, n = 7; WKY, n = 7; PRET , n = 7)

*p

< 0.01;

**p

< 0.0 5

Dec~ine

0\
-...J

Table 14
Percentage of Control Data for the Effects of H¥poxia on
Papillary Muscles Exposed to 2.5mM Ca+

Time
(min)
5

30

60

Resting
Tension
(gjrnrn2)

Rat .
Type

Developed
Tension
( gjrnrn2)

Maximal Rate
of Tension
Development
(gjrnrn2sec)

Maximal Rate
of Tension
Decline
(g/rnrn2sec)

Time to
Peak Tension
(msec)

Time to Half
Relaxation
(msec)

Time to
Maximal
Relaxation
(msec)

WKY

106 .7 +

8.8

85.0 + 7.1

84.0 + 6.9

85.4 + 5.7

95.7 + 2.5

98.2 + 10.5

94 . 7 + 12.5

SHR

113.4 +

5.2

64.2 + 5.0

62.7 + 4.9

67.6 + 5.2

95 .5 + 3.5

109.9 + 10.6

126.4 + 19.8

PRET

112 . 3 +

5.9

62 . 7 + 5 . 7

62.8 + 7.7

67.1 + 5.7

94.5 + 3.3

96.4 +

7.9

103.3 + 12.0

WKY

98.5 +

6.7

42.9 + 9.4

41.1 + 5.6

43.9 + 4.6

93.4 + 2.3

92.1 +

6.1

101.0 + 13.5

SHR

114.1 +

7.2

39.1 + 5.8

35.1 + 3.8

43.3 + 6.2

91.6 + 1.4

102.6 +

9.3

108.4 + 23.8

PRET

121.1 +

6.7

31.4 + 4.1

31.6 + 4.0

39.9 + 4.7

85.4 + 3.2

92.3 +

8.5

110.2 +

WKY

110.2 + 12.9

3 8 .5 + 6.6

36.2 + 4.3

46.2 + 3.4

91.5:!:. 2.7

93.7 + 12.3

87.6 + 14.8

SHR

113.6 +

8.6

34 . 2 + 6.6

33.6 + 5.1

42.0 + 5 .5

94.8 + 3.3

94.0 +

9.4

109 . 1 + 19.8

PRET

137.1 + 12 . 0

31.6 + 4.7

32.5 + 4.4

41.7 + 6.0

89.6 + 2.5

108.7 +

9.8

97.2 +

8.9

8 .9

Data are me an + standard error
(SIIR, n

=

7; WKY, n

=

7; PRET, n

=

7)

~
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expresses this data as percent of control.

Table 13 shows

that RT of PRET increased significantly at 60 minutes of
hypoxia.

It shows that the +dT/dt, an indication of con-

tractility, was significantly lower than the controls in
all three groups of rats (WKY, SHR, and pretreated rats)
after 5, 30, and 60 minutes of hypoxia.

Figures 8 and 9 do

not show any significant difference between WKY and SHR,_
WKY, and pretreated rats, and SHR and pretreated rats after
60 minutes of hypoxia, but after 5 minutes of hypoxia
(Table 14), a significant difference (p < 0.05) in DT and
+dT/dt between SHR and WKY was observed.

Both DT and

+dT/dt were greater for WKY than for SHR -(Table 14). During
hypoxia, the TPT, RT%, TPR and, therefore, the contraction
cycle, were shortened.

There was a significant difference

(p < 0.01) _before and after hypoxia.

Readings before hypoxia

were higher than those after hypoxia.
Tables 15 and 16 show reoxygenation after hypoxia.
Table 15 shows that the RT of PRET which increased significantly at 60' of hypoxia decreased significantly at 30' of
reoxygenation.

During reoxygenation the parameters of

muscle mechanics all increased and reapproximated their
prehypoxic state.

All the parameters except for the rest-

ing tension were significantly higher than their controls.
As seen in Figures 8 and 9, the WKYs, SHRs, and pretreated
rats responded almost equally to reoxygenation.

No signi-

ficant difference was observed between the three groups of
rat.

Table 15
The Effects of Reoxygenation on Papillary Muscles Exposed to 2.5mM Ca++

Developed
Tension
(gj mm2)

Maximal Rate
of Tension
Development
(gj mm2sec)

Maximal Rate
of Tension
Decline
(gj mm2sec)

Time to
Peak Tension
(msec )

Time to
Maximal
Relaxation
(msec)

Time
(min)

Rat.
Type

Resting
Tension
(gjmm2 )

CONTROL

WKY

0.81 + 0.11

0.87 + 0.18

10.84 + 2.07

8.17 + 1.61

139.29 + 5.04

80 .71 +

5.16

206.43 + 22.32

SHR

0.75 + 0.17

0.60 + 0.10

6.81 + 0 . 93

5.73 + 0.71

152.14 + 6.88

85.00 +

7.23

207.14 + 14. 36

PRET

0.85 + 0.05

0.65 + 0.09

8.19 + 1.42

6.31 + 0 .72

138.66 + 4.29

91.97 +

4.86

197.50 + 1 6.90

WKY

0. 77 + 0 . 13

2.21 + 0.83*

SHR

0.72 + 0.20

2.14 + 0.53 *

PRET

0.81 + 0 . 06

1 . 79 + 0.24*

5

10

15

30

-

23.57 + 7.09 *

15 . 26 + 6 . 47 * 150.71 + 5.16

24.33 + 5.84 *

Time to Half
Relaxation
(msec)

20.83 + 3.14*

97.14 +

6.52

245.71 + 18.31

13 . 84 + 2.83* 161.43 + 6.60

107.86 +

8.77

248 .57 + 25.98

11.87 + 0.96* 155.96 + 6.21

101.29 +

3.10

247.26 + 13.55

-

-

-

WKY

0.76 + 0.13

2 .67 + 0.70*

31.74 +

7 .32'~

18 . 46 + 5.81* 150.00 + 5.11

95.00 + 11.88

250.71 + 2 j.23

SHR

0.73 + 0.23

2 . 16 + 0.48*

25.19 + 5.05 *

15.26 + 2.71* 160.71 + 6.57

102.86 + 10.44

262.14 + 31.81

PRET

0.77+0.06

2. 2 6 + 0.36 *

27.44 + 4.71'''

15.07 + 1.44* 149.87 + 4.33

WKY

0.71 + 0 . 13

2.82

SHR

0.78 + 0.25

2 .11 + 0.47*

PRET

0. 77 + 0.06

-

-

-

-

93.69 +

6.67

241.63 + 21.71

5.94

87.14 +

-

8 .9 1

248.57 + 25.70

24.67 + 5.17 *

15.20 + 2.79* 157.14 + 6.34

98.57 +

-

9.03

229.29 + 22.47

2.36 + 0.37 *

-

29 .47 + 5.38 *

17.03 + 1.79 * 147.87 + 4.45

8 3.59 +

5.12

222 .0 1 + 19.79

±

o.65*

-

34.81

±

7 . 54 *

20.40

±
-

5.5o* 146.43

±
-

-

WKY

0.70 + 0.14

2 . 93 + 0.61'""

37.46 + 7.49 ''<

80.71 +

7.26

220.00 + 11.98

0.77 + 0.28

2. 10 + 0.47 "''

-

22.54 + 5.34* 144 .23 + 6.11

SHR

25.70 + 5.28'"

17.17 + 3.33* 147.86 + 4. 20

96.43 +

6.69

22 0.00 + 1 7 . 70

PRET

0.72 + 0.04 '''

2 .18 + o.44 *

3 l .o o + 5.88 *

18.74 + 2.32* 138.84 + 4.12

78.01 +

4.35

21 7.83 + 15.54

Da t a are mean

~

-

-

standard error

(SHR, n = 7; WKY , n
*p < 0 . 0 1;

-

=

7 ; PRET , n

=

7)

**p < 0 . 05
-....)

0

Table 16
Percentage of Control Data for the Effects of Reoxygenation on
Papillary Muscles Exposed to 2.5mM ca++

Time
(min)
5

10

15

30

Resting
Tension
(g/mm2)

Rat.
Type

Developed
Tension
(g/mm2)

Maximal Rate
of Tension
Develofment
(g/mm sec)

Maximal Rate
of Tension
Decline
(g / mm2sec)

207.3 ± 44.1
323.0:!: 63.7
277 .7 ± 33.0

164.2 :!: 42.2
223.6 :!: 30 .9
20 1 .4 ± 26.4

Time to Half
Relaxation
(msec)

Time to
Maximal
Re la xation
(msec)

108 . 6 ± 3.5
107.0:!:: 4.7
112.5 :!: 3.1

12 5 .1:!: 12 .7
136.7 ± 22.6
112.3 ± 7.6

127.1 :!: 15 . 7
120 . 4 :!: 11 . 3
130.0 ± 12 . 7

Time to
Peak Tension
(msec)

WKY

93.0

~

7.0

SHR
PRET

94 . 0 :!:
93 . 0 ~

5. 6
2. 5

230.2 ~ 49.7
327.0 ~ 47 .1
301. 6 ± 44.4

WKY
SHR

91.3 :!: 10.0
91.6 ± 7 . 8

299.4 ~ 49.7
348 . 6 ± 49.7

290.5 ~ 5 1.1
353.9 :!: 54.0

2 11. 4:!: 37.7
253 . 4 ± 24.4

108 .0 ± 3.0
106.0 :!: 6.2

1 22.2 :!: 19.6
1 32.3 :!:: 25 . 0

128 . 1 :!: 15. 1
127.9 ± 16.8

PRET

89.2 ~

3 .6

361.1:!: 41.9

350.5 ± 30 .9

251 . 8 :!: 32.2

108 . 3:!:: 2.7

104. 1 ± 10 . 4

127.8 :!: 17.3

WKY

85.6 ~

9. 9

320.9 :!: 46.4

316.6 ± 48.4

238 . 4:!: 33 . 1

105.2 :!: 2.6

111.4

± 14 .6

129.6 ± 18 . 4

SHR

253 . 9 ± 27 . 8

103 . 5 ± 5.6

1 22 . 0 :!: 16.8

113.0:!: 1 3 . 1

8.3
3. 6

62.1

PRET

95 . 5 ±
89.2 ±

35 4.4 :!: 64.3

366.3:!: 3 1 .9

357 .2 :!: 22.5

28 1.1 :!: 32 . 9

106.8 :!: 2.4

WKY

83 .7:!: 11.5

344.4 ± 40 . 2

349.0:!: 41.6

275 .7:!: 27.0

102.9 :!: 3 . 5

105.1 ± 11.2

11 3 .6

SHR
PRET

92 . 6
84.2

±
±

351. 7:!: 69 . 9
361.0:!: 29 . 0

371 . 8:!: 70 .4
378.9 ± 28 . 5

286.7 ± 37.6
304. 1 :!: 32.1

97 . 4:!: 6. 1
98 . 8:!: 1 . 9

12 1. 2 :!: 17.0
86.4 ± 7.0

108. 5 ± 11 . 1
1 13 .5 ± 9.4

10 . 8
3 .8

348 .9

~

93.2 ±

9 .1

11 5 .4:!: 1 3 .0

± 12 . 1

Data are mean ± standa rd er r or
(SHR , n

=

7 ; WKY, n

=

7; PRET, n

=

7)

-...]
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Chapter 4
DISCUSSION
Clonidine effected a significant decrease (p < 0. 01 >.
in the blood pressures of spontaneously hypertensive rats
after chronic treatment, as was shown by Dadkar, Aroskar,
and Dohadwalla (1979), who administered clonidine orally
for 5 days to SHRs.

The only problem encountered with this

treatment was that most of the rats died during blood
pressure monitoring.

All showed the same pattern of

"frothing,. from nose and mouth before dying.
hemorrhage was found in their lungs.
to explain this effect.

At autopsy,

No data has been able

Possibly the sensitivity of the

rat to heat may be affected by the continuous administration of clonidine.

This may indicate thermoregulatory

dysfunction in SHRs which may be of central origin.

It is

known that SHRs have a higher basal body temperature and
are more sensitive to heat (O'Donnell and Volicer, 1981;
Wilson, Wilson, and DeCara, 1977; Wright, Lams, and Knecht,
1977).

O'Donnell and Volicer (1981) showed that treatment

with clonidine and other antihypertensives decreased the
blood pressures of SHRs but did not normalize body temperatures or heat sensitivity.
Alpha-methyldopa produced a significant hypotensive
effect on the blood pressures of the SHRs in this study.
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Other investigators (Day, Roach, and Whiting, 1972;
Filczewski and Boqucka, 1979; Zavisca et al., 1979) have
also shown hypotensive effects of alpha-methyldopa in the
SHR.
Verapamil was found to be very effective in causing
a significant decrease in blood pressure.

Data pertinent

to the hypotensive action of verapamil following long-term
oral therapy are few.

Nevertheless, in several studies

with the drug in angina, blood pressure was found to be
lowered by verapamil when administered to mildly hypertensive patients with ischemic h e art disease (Hoffman, 1964;
Lewis, 1978; Lewis et al., 1979; Livesley et al., 1973;
Tschirdewahn and Klepzig; 196 3 ).

Oates, Stoker, and

Stokes (1979), using unanesthesized rats, also showed that
verapamil can be an .effective hypotensive agent.
Propranolol treatment produced variable effects on
the blood pressures of spontaneously hypertensive rats.
This variability of response was consistent with some
previous reports (Forman and Mulrow, 1974; Levy, 1976;
Numao and Iriuchijima, 1974).

Others (Garvey and Ram,

1975; Sweet et al., 1976; Vavra, Tom, and Greslin, 1973)
showed that propranolol had a hypotensive action on the
blood pressure of spontaneously hypertensive rats.

Hypo-

tensive action was also observed by Smits, Van Essen, and
Struyker-Boudier (1980) when propranolol was delivered for
5 days to conscious, unrestrained spontaneously hypertensive
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rats using osmotic minipurnps.

Close comparison of the

results of these studies is hampered by differences in
experimental conditions, such as the use of anaesthetics,
methods of pressure measurement, dosages used and the
schedule of drug administration.
Cardiac hypertrophy, which has always been associated with hypertension, is also present in the spontaneous
hypertensive rat.

This rat, therefore, offers a unique

model for studying the reversal of cardiac hypertrophy by
medical therapy.

Systematic investigation led to the

suggestion that factors other than arterial pressure are
involved in the development of cardiac hypertrophy in
hypertension (Sen et al., 1974).

Results of the present

study showed that the antihypertensive drugs used to treat
the SHRs chronically did not cause a significant reduction
of heart weight to body weight ratio.

This finding

suggests that decreasing blood pressure by pharmocologically
alone, at least for a 6-week period, may not reverse hypertrophy.

On the other hand, the mechanism of action of the

antihypertensives--such as the effect on hemodynamic,
humoral, and/or neurogenic factors--might also be very
important in reversing cardiac hypertrophy.

A biochemical

effect of the drugs on cardiac muscle is another possibility.
Sen et al.

(1977) carne to the tentative conclusion that

sympathetic stimulation and hemodynamic factors might play
more important roles.
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In spontaneously hypertensive rats, the abilities
of the cardiac and vascular smooth muscle to retain calcium
(by depressed calcium binding and accelerated ATP splitting) and to take ATP-dependent calcium into the sarcoplasmic reticulum are less than those of normotensive rats
(Aoki et al., 1974a, 1974b; Aoki, Yamashita, and Hotta,
1976; Moore et al., 1975).

The way in which SHRs and WKYs

handle calcium during a cardiac cycle can be affected by
different pharmacologic or physiologic interventions.
Isoproterenol, a beta-receptor agonist, has a
positive inotropic effect on the myocardium of most species.
Isoproterenol relaxes almost all varieties of smooth muscle.
Isoproterenol has a relax ing effect on the isolated thoracic
aorta.

Spector e t al.

(1969) found this relaxing effect

greater for SHRs than for WKYs.

Others found the relaxa-

tion of the SHR thoracic aorta to be l ess than that of the
WKY (Cohen and Berkowitz, 1976; Triner et al., 1975); still
others found that relaxation was equa l in both SHR and WKY
(Levy, 1974; Shibata, Juraha shi, and Kuchii, 1973).

Limas

and Limas (1978) observed a decreas e d numb er of betareceptors in the hearts of SHRs, and therefore a decreased
sensitivity to catecholamines.

Since isoproterenol causes

the stimulation of beta-receptors, its effect is necessarily lower in SHR than in WKY, due to the decreased
numbe r of beta-receptors.

In the present study, a few

minutes after isoprotere nol was added to the papillary
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muscle in the absence of propranolol, a significant change
in performance from control was observed in both the SHR
and WKY.

The tension developed by the papillary muscles

of both SHR and WKY was only moderately depressed.
depression was equal in both SHR and WKY.

The

Overall con-

tractility (+dT/dt) was not depressed in WKY but was
depressed at 15 minutes in the SHR.

Fifteen minutes after

the addition of isoproterenol, the time to peak r e laxation
of papillary muscles from WKYs was significantly d e pressed
when compared to their control.

The time to half relaxation

of the papillary muscles showed that 1 minute after the
addition of isoproterenol to the bath, the WKY responded
significantly differently from the SHR.

The time to half

relaxation was longer for WKY than for SHR, but after
several minutes, the time to half relaxation became almost
equal for the SHR and WKY.
Propranolol, that was added to muscle bath, causes
beta adrenergic receptor blockade, which produces metabolic rearrangements in myocardial cells and also decreases
penetration of ionized calcium into the cytoplasm
(Kukovetz and Poch, 1976).

Propranolol has been shown to

cause negative chronotropic and inotropic effects.

The

results of the present study indicate that the developed
tension of papillary muscles from WKY and SHR were
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significantly depressed at 1 and at 5 minutes following
propranolol addition, whereas the developed tension of
muscles from SHR only was significantly depressed 10
minutes after the addition of propranolol.

This result

indicates a possible difference in sensitivity to receptor
sites.

Propranolol also caused significant decrease in

+dT/dt of the WKYs and SHRs after 5 minutes addition,
indicating significant relaxation.

Ten minutes following

this intervention, only the dT/ dt and -dT/ dt of the WKY
was significantly decreased.

Also the TPR of SHRs were

significantly decreased after 10 minutes of addition.

A

significant difference (WKY lower than SHR) in the developed
tension of the WKYs and SHRs was noted 5 minutes following
intervention with propranolol.

This result suggests a

difference in the sensitivity to propranolol of the betareceptors of SHRs and WKYs.
When isoproterenol was added to the bath after
propranolol, only the muscles from the WKYs showed a
significant recovery from the effect of the propranolol.
This also suggests a possible difference in the way WKYs
and SHRs respond to propranolol.
Acidosis resulted in a significant decline in
muscle contractility.
Williamson et al.

Nakamuru and Schwartz (1970) and

(1975) suggested that, at low pH, excess

hydrogen ions compete with calcium ions for binding sites
to the myocardial protein troponin and increase the binding
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of calcium ions to the sarcoplasmic reticulum.

The present

study showed that after 5 minutes of acidosis, the developed
tension and the rate of tension development of only the
pretreated rats were significantly depressed compared to
their control.

After 30 minutes of acidosis, the developed

tension of the SHRs and pretreated rats were significantly
depressed when compared to their controls, while the +dT/dt
of only the pretreated rats was significantly depressed.
At 60 minutes of acidosis, the maximal rates of tension
development of all the three groups of rat were depressed
significantly.

The present study also found that the rate

of tension development of the WKY was significantly less
than that of the SHR at 30 and at 60 minutes of acidosis.
The rate of tension decline was also significantly lower for
both the WKY and the pretreated rat and higher for the SHR.
These results suggest a difference in the way the WKYs,
SHRs and pretreated rats respond to acidosis:

SHRs

appeared to be less sensitive to the depressing effects of
acidosis.

Figures for developed tension and rate of ten-

sion development indicate a difference in amount/rate of
intracellular calcium release, suggesting that the differences among these groups in response to acidosis has something to do with the handling of calcium.
An increase in extracellular calcium resulted in
improvement in every area of muscle performance studied.
Developed tension and maximal rate of tension development
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were significantly increased for the WKYs, SHRs, and pretreated rats.

The three groups of rats responded almost

equally to this intervention.

Increased extracellular

calcium did not override the effects of acidosis as well in
SHRs as in the other groups, indicating a difference, at
least during acidosis, in their responsiveness to increased
calcium.
Hypoxia caused a significant decline in performance
in all areas studied.

Hypoxia decreases tissue oxygen

availability while reoxygenation elicits rapid increases
in tissue consumption (Whaler, 1967).

Because oxygen is

needed for oxidative phosphorylation, hypoxia results in
decreased amounts of energy available for the contractioncoupling process.

Tyberg et al.

(1969, 1980) studied the

effects of hypoxia on papillary muscle mechanics and hypothesized that a reduced amount of calcium might enter the
myoplasm during hypoxia, activating only the peripheral
portions of the myofibrils.

The present study found that at

5, 30, and 60 minutes of hypoxia, the DT and +dT/dt were
significantly depressed for the WKYs, SHRs, and pretreated
rats.

SHRs, pretreated rats, and WKYs responded differently

in the early stages of hypoxia, but this was a transient
effect.

Perhaps in the early stages of hypoxia SHRs

experienced more rapid depletion of available o 2 .

Since

calcium stores were more rapidly depleted in SHR, there
should have been a decrease in developed tension.

Depletion
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was further compounded by the acidic medium.
calcium resulted in less ATP.

Nayler et al.

Lowered
(1979) showed

that mild acidosis has a protective effect on hypoxic heart
muscle, resulting in a relatively small rise in resting
tension.

The present study found a small rise in resting

tension of the WKY, and, in the SHR, a greater rise at 5
minutes of hypoxia and then a smaller rise with time.

This

difference, observed at the early stage of hypoxia, indicates
that acidosis did not have much protective effect in SHR.
When muscles were reoxygenated after hypoxia,
performance parameters reapproached prehypoxic values to
varying degrees.

SHRs, WKYs and pretreated rats responded

almost equally during reoxygenation.

Nayler et al.

(1979)

observed a greater recovery of tension development during
reoxygenation when hypoxia occurred at acidic pH than when
it occurred at normal pH.

Lakatta, Nayler, and Poole-Wilson

(1979), measuring mechanical function and calcium accumulation in isolated normotensive muscle, found that when
hypoxia was induced at low pH (6.8), subsequent reoxygenation at normal pH was not associated with calcium overload
or the development of contracture.

The phenomenon of

calcium overload during hypoxia and reoxygenation has not
been examined in hypertensive cardiac muscle, but the results
of the present study show that SHR behaved differently from
WKY during hypoxia and subsequent reoxygenation, suggesting
that acidosis has less protective effect on SHR.

Chapter 5
SUMMARY OF RESULTS AND CONCLUSIONS
1.

Clonidine, alpha-methyldopa, and verapamil

reduce blood pressure of SHRs.
2.

Isoproterenol did not have a significant

inotropic effect on isolated cardiac muscle obtained from
SHRs or WKYs.
3.

Propranolol significantly depressed +dT/dt only

in the WKYs, showing that SHRs behave differently from WKYs.
4.

Acidosis significantly depressed muscle

performance in SHR, WKY, and pretreated papillary muscles.
However, +dT/dt and -dT/dt were decreased significantly
less in the SHR than in the other groups, indicating that
SHRs are less sensitive to acidosis.
5.

Increasing extracellular calcium from 1.0 to

2.5 mM significantly increased the inotropic state of all
three groups of muscles.
6.

Hypoxia during acidosis significantly decreased

muscle performance in all three groups.

At 5 minutes

hypoxia, however, WKY was less depressed than SHR; this
shows that WKYs are less sensitive to hypoxia.
7.

Reoxygenation at normal pH resulted in muscle

improvement of a similar magnitude in all three groups, and
no increases in resting tension were observed, indicating
81
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that acidosis has a protective effect on muscles made
hypoxic, thereby preventing contracture and subsequent
death of the muscle during reoxygenation at normal pH.
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